<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191163</url>
  </required_header>
  <id_info>
    <org_study_id>1138.3</org_study_id>
    <nct_id>NCT02191163</nct_id>
  </id_info>
  <brief_title>Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency</brief_title>
  <official_title>A 17 Week, Randomised, Double-blind, Placebo Controlled Cross-over Trial to Evaluate the Efficacy of Antistax® Film Coated Tablets (Extr. Vitis Vinifera Siccum), 360 mg/Day p.o. in Improving Microcirculation of the Skin in the Leg of Male and Female Patients Suffering From Chronic Venous Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the efficacy and safety of Antistax® film coated tablets in improving
      microcirculation of the skin in the leg of patients with chronic venous insufficiency (CVI)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in the resting flux</measure>
    <time_frame>Baseline, after 6 weeks of treatment</time_frame>
    <description>measured in the frequency range 10-37 kHz on the skin of the inside lower leg using the Laser Doppler Fluxmetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the resting flux</measure>
    <time_frame>Baseline, after 3 weeks of treatment</time_frame>
    <description>measured in the frequency range 10-37 kHz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the resting flux</measure>
    <time_frame>Baseline, after 3 and 6 weeks of treatment</time_frame>
    <description>measured in the frequency range &lt;10 kHz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the combined resting fluxes (&lt;37 kHz)</measure>
    <time_frame>Baseline, after 3 and 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the transcutaneous oximetry (TcPO2)</measure>
    <time_frame>Baseline, after 3 and 6 weeks of treatment</time_frame>
    <description>measured on the inside lower leg of the more CVI-affected leg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the calf circumference of the most affected leg</measure>
    <time_frame>Baseline, after 3 and 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the ankle circumference of the most affected leg</measure>
    <time_frame>Baseline, after 3 and 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)</measure>
    <time_frame>Baseline, after 3 and 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global efficacy assessment by patient on a 4-point verbal rating scale (VRS)</measure>
    <time_frame>after 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global efficacy assessment by investigator on a 4-point VRS</measure>
    <time_frame>after 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant changes in laboratory values</measure>
    <time_frame>Baseline, up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>Baseline, up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global tolerability assessment by investigator on a 4-point VRS</measure>
    <time_frame>after 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global tolerability assessment by patient on a 4-point VRS</measure>
    <time_frame>after 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>Antistax®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 360 mg for 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antistax®</intervention_name>
    <arm_group_label>Antistax®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  &gt;= 18 years of age

          -  CVI I or CVI II (without expanded trophic disturbances)

          -  Willing and able to give written informed consent in accordance to Good Clinical
             Practice and local legislation prior to participation in the study

        Exclusion Criteria:

        Concomitant disease(s) exclusion criteria:

          -  Decompensated cardiac insufficiency

          -  Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal
             insufficiency, lymph edema, etc)

          -  Peripheral arterial disease (ankle/arm pressure index &lt; 0.9)

          -  Current acute phlebitis or thrombosis

          -  Renal insufficiency (Serum creatinine &gt; 1.5 mg/dl)

          -  Liver disease (SGPT (ALAT) &gt; 3x upper limit of normal)

          -  Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or
             hypocalcaemia, malignancies

          -  Anamnestic indications of diabetic microangiopathy or polyneuropathy

          -  Drug and/or alcohol abuse

          -  Pregnant or nursing women or inadequate birth control methods (this applies to females
             of childbearing potential only)

          -  Severe climacteric complaints or changes in, or initiation with post-menopausal
             hormone replacement therapy within the last 3 months

          -  Immobility

          -  Avalvulie

          -  Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus,
             Haemangiectasia hypertrophicans)

          -  State after pulmonary embolism

          -  Recognized hypersensitivity to the trial drug ingredients

          -  Current florid venous ulcus

          -  Clinical indication for a necessary, specific phlebologic acute treatment, e.g.
             compressive treatment, phlebectomy, etc.

        Previous treatment(s) exclusion criteria:

          -  Treatment with venous drugs within the last 4 weeks

          -  Changes in, or initiation with, treatment with theophylline, diuretics, cardiac
             glycosides, ACE inhibitors or calcium antagonists within the last 8 days

        Concomitant treatment/non-drug therapy exclusion criteria:

          -  Other venous drugs apart from the trial medication

          -  Compression bandages

          -  Venous surgery of the leg used for the fluxmetry

          -  Extensive use (i.e. on more than a total of 6 days during the entire trial) of
             laxatives which affect fluid or electrolyte balance

          -  Major surgery requiring full anesthesia

        Other exclusion criteria:

          -  Previously studied under this protocol

          -  Participation in another clinical trial within the previous 90 days or during the
             present study

          -  Patients considered as mentally ill as well as unable to work or with limited working
             ability, or unable (or only partially able) to follow the spoken or written
             explanations concerning the trial

          -  Patients in a bad general health state according to the investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

